Overall, galectin-3-mediated endothelial dysfunction contributes significantly to the pathogenesis of diastolic dysfunction and cardiovascular diseases, underscoring its potential as a therapeutic target for mitigating vascular inflammation and improving endothelial function. This evidence concerns the gene LGALS3 and cardiovascular disorder.